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Introduction
The prevention of chronic disorders is one of the most 
important cornerstones of primary health care. Screening 
for microalbuminuria is valuable in primary health care, 
as microalbuminuria is the earliest manifestation of 
nephropathy, and an independent marker of increased 
cardiovascular morbidity and mortality in diabetic,1 as well as 
non-diabetic, patients.2 The presence of microalbuminuria 
serves as a signal for vascular disease screening, as well 
as aggressive intervention to reduce all cardiovascular 
risk factors. Early detection of microalbuminuria is crucial, 
as optimal treatment of these patients can slow the 
development of and progression to persistent albuminuria 
(overt nephropathy), and reduce cardiovascular risks.1
Microalbuminuria is a persistent, increased urinary excretion 
of albumin above the reference range for healthy non-
diabetic subjects, but at a concentration that is not generally 
detectable by crude clinical tests, such as dipsticks 
designed to measure total urine protein. The reference point 
for albuminuria remains the accurate collection of a timed 
or 24-hour urine specimen, but this is cumbersome for the 
patient, and a difficult procedure to control effectively. This 
is because the urine is frequently over- or undercollected, 
with subsequent over- or underestimation of albumin. Since 
the creatinine excretion in urine is fairly constant throughout 
a 24-hour period, measurements of the albumin-to-
creatinine ratio (ACR) allow correction of variations in urinary 
concentration, avoiding the confounding effect of variations 
in urine volume on the urine albumin concentration (Table I 
shows the diagnostic thresholds). 
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The assessment of cardiovascular risk factors and renal 
damage is a common task in general practice. In a clinic 
setting, screening needs to be simple and cost-effective 
with acceptable accuracy. There is an increasing demand 
for urine albumin tests that are suitable for point-of-care 
testing (POCT). The advantage of POCT for detecting 
microalbuminuria is rapid results, and thus immediate 
motivation for lifestyle changes by the patient, and the 
possibility of early intervention, with the goal of delaying the 
onset of overt nephropathy and reducing the cardiovascular 
risks. In this study, we evaluate two POCT instruments 
that are currently available for albuminuria detection, 
the HemoCue® urine albumin analyser, and Clinitek® 
microalbumin reagent strips, 
Method
Urine specimens
Spot urine specimens of diabetic patients received at the 
National Health Laboratory Services (NHLS), Universitas 
Hospital, Bloemfontein, for the routine analysis of albuminuria 
were used. The specimens were obtained between July 
2007-August 2008. The number of specimens analysed 
by the POCT instruments were subject to the availability 
of reagents for the respective POCT instruments at that 
time. The study was approved by the ethics committee of 
the Faculty of Health Sciences of the University of the Free 
State.  
Sample processing
All received specimens were kept at 4°C until analysis. 
Analysis was carried out within 48 hours of the specimens 
being received. Turbid specimens were centrifuged, and 
all specimens were allowed to warm to room temperature 
before analysis. The urine specimens were first screened 
for proteins with the Bayer Diagnostics (Siemens) Multistix 
standard urine protein reagent strip. All specimens screened 
for proteinuria with results 3+ (corresponding to urine 
proteins > 3.0 g/l), or greater, on the dipstick were excluded 
from the study.
Laboratory urine albumin and creatinine method
• Urine creatinine concentration (mmol/l) was 
measured on the Beckman-Coulter LX20® (modified 
Jaffe method).
• Urine albumin concentration (mg/l) was measured 
on the Dade Behring BN Prospec® Nephelometer 
(immunonephelometry).
• ACR was calculated and expressed as mg albumin/
mmol creatinine.
POCT urine albumin and creatinine method
All urine specimens were analysed according to the 
manufacturer’s instructions with the HemoCue® 201 
urine albumin (HemoCue®, Ängelholm, Sweden) POCT 
system and Clinitek® microalbumin urine reagent strips, 
read by the Clinitek® status urine chemistry reflectance 
photometer (Siemens® Medical Solutions Diagnostics, 
formerly Bayer).   
The HemoCue® 201 urine albumin analyser is a POCT 
system that measures urine albumin quantitatively, 
using specially designed micro-cuvettes that contain an 
immunochemical antigen-antibody reaction using antihuman 
antibodies specific to human albumin. This reaction forms 
agglutination complexes that create turbidity, which is read 
by the HemoCue® albumin 201 photometer. The turbidity is 
proportional to the concentration of albumin in urine. The 
sample volume is 18 µl, and results are displayed within 90 
seconds. The HemoCue® albumin 201 measurement range 
is 5-150 mg/l. To obtain results above 150 mg/l, specimens 
can be diluted with isotonic sodium chloride, and the results 
multiplied manually by the dilution factor.4
The Clinitek® microalbumin urine reagent strips contain 
two reagent areas to test for albumin and creatinine in 
urine respectively. The semiquantitative results are read by 
a Clinitek® status reflectance photometer and the results 
are expressed within 60 seconds as an ACR in mg/mmol. 
The ACR is determined by the instrument via photometry, 
and it is not merely a calculation of the semiquantitative 
values assigned to albumin and creatinine. The results are 
expressed as “normal” (ACR < 3.4 mg/mmol), “abnormal” 
(ACR 3.4-33.9 mg/mmol) and “high abnormal” (ACR 
> 33.9 mg/mmol).5
Table I: Diagnostic thresholds for urine albumin excretion1,3 
aCategory 24-hour urine albumin (mg/24 hours) Overnight/timed urine albumin (µg/minute)
Spot urine
Urine albumin (mg/l) bACR  (mg/mmol)
Normal < 30 < 20 < 20 < 3.4
Microalbuminuria 30-299 20-199 20-199 3.4-33.9
Macroalbuminuria > 300 > 200 > 200 > 34.0
a = two of three urine specimens collected within a three-to-six-month period should be abnormal before diagnosing microalbuminuria, b = albumin-to-creatinine ratio
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Quality control
The NHLS Department of Chemical Pathology belongs to an 
external quality assurance scheme (EQAS) for both the urine 
creatinine and albumin analytes, and runs a daily internal 
quality-control programme. Performances for the period of 
the study were within acceptable limits. The reproducibility 
of the HemoCue® POCT system was assessed by analysing 
two levels of control material with each batch of specimens. 
The overall coefficient of variation (CV) was calculated. The 
repeatability of the Clinitek® microalbumin POCT system 
was evaluated by analysing urine specimens with different 
concentrations of albumin and creatinine repeatedly, and 
comparing the semiquantitative results. The linearity, 
detection limits and reportable range of both POCT 
instruments for urine albumin were confirmed by making 
serial dilutions of 20% human albumin stock solution with 
0.9% sodium chloride. The concentrations of the dilutions 
were confirmed with the laboratory nephelometric method.
Data analysis
All the data were captured on Excel spreadsheets. A 
urine albumin concentration of less than 20 mg/l, or less 
than 3.4 mg/mmol creatinine, was regarded as normal, 
with microalbuminuria defined as a concentration of 
20-199 mg/l or 3.4-33.9 mg/mmol creatinine. The two 
POCT results were compared with the laboratory-measured 
albumin and creatinine concentrations, and correlations 
with quantitative values were carried out by means of 
linear regression and Bland-Altman plots. The sensitivity, 
specificity, predictive values and likelihood ratios for 




Two hundred and forty-five urine specimens were tested on 
the HemoCue® urine albumin analyser (measurement range: 
5-150 mg/l):
• Forty-three specimens (43) tested < 5 mg/l. 
• One hundred and ninety-one specimens (191) tested 
5-150 mg/l.
• Eleven specimens (11) tested > 150 mg/l.
Table II and Figure 1 illustrate the results of the HemoCue® 
urine albumin compared to the laboratory-determined 
albumin concentration at a cut-off of 20 mg/l for 
microalbuminuria. The sensitivity of the HemoCue® test 
was 79.6%, and specificity was 97.1%. There were 4.4% 
false positives, and 14.2% false negatives. However, it is 
noteworthy to mention that most of the specimens that 
tested falsely negative with the HemoCue® method had 
a laboratory albumin concentration just above the cut-off 
point of 20 mg/l.
There was adequate correlation between the HemoCue® 
and the laboratory quantitation of urine albumin (see Figure 
2), with a correlation coefficient of 0.97, and no significant 
constant bias (intercept) of 0.25 (95% confidence interval 
1.4-1.9). The laboratory method gave slightly higher values 
at high urine albumin concentrations (see Figure 3) with a 
proportional bias (slope) of 0.86 (95% confidence interval 
0.82-0.89).
Two levels of control material were analysed with each 
batch of specimens on the HemoCue® POCT system as 
part of internal quality control. The overall CV was 13.1% at 
27 mg/l (n = 16) and 6.4% at 86 mg/l (n = 17).
Table II: Distribution of urine albumin analysed by the HemoCue® POCT method and the laboratory methods, with a cut-off point of 20 mg/l for microalbuminuria
Laboratory albumin < 20 mg/l 
microalbuminuria negative
Laboratory albumin ≥ 20 mg/l 
microalbuminuria positive Total












Total 137 108  245
Figure 1: HemoCue® urine albumin vs. laboratory urine albumin in mg/l
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Clinitek® microalbumin POCT system
Two hundred and four urine specimens were analysed by 
the Clinitek® microalbumin urine dipstick POCT system:
• One hundred and thirty-four specimens (134) tested 
normal (ACR < 3.4 mg/mmol).
• Sixty specimens (60) tested abnormal (ACR 3.4- 
33.9 mg/mmol).
• Ten specimens (10) tested high abnormal (ACR  
> 33.9 mg/mmol).
Figure 4 and Table III illustrate the results of the Clinitek® 
microalbumin ACR compared with the quantitated laboratory 
ACR at a cut-off of 3.4 mg/mmol for microalbuminuria. The 
sensitivity and specificity for the Clinitek® microalbumin 
POCT system were respectively 83.8% and 93.8% with 
false positive and false negatives of 11.4% and 9.0% 
respectively.
The repeatability of the Clinitek® microalbumin dipstick 
was evaluated using patient urine specimens with 
different concentrations of albumin and creatinine, 
as well as positive and negative ACRs. The Clinitek® 
microalbumin dipstick gave excellent repeatability 
(n = 10) on different levels of the semiquantitative albumin 
and creatinine concentrations, as well as ACRs.
Discussion
There is increasing evidence that suggests that the 
detection and treatment of microalbuminuria in diabetic 
patients is important in identifying patients at increased 
risk of both micro- and macrovascular disease, and to 
prevent or slow the progression of vascular damage.1,2 
POCT of microalbuminuria allows immediate identification 
of the  risk and monitoring of the treatment effects. In this 
study, the goal was to evaluate two new office-based 
methods to assess urinary albumin excretion. 
The HemoCue® albumin 201 is a POCT method for the 
quantitative determination of albumin in urine (measuring 
range 5-50 mg/l), using an immunochemical method. 
Figure 4: Laboratory quantitative albumin-to-creatinine ratio (ACR) versus 
Clinitek® semiquantitative ACR (mg/mmol)
Figure 2: Correlation between urine albumin concentrations measured by 
the laboratory (BN ProSpec® Nephelometer) and the HemoCue® POCT 
methods
Figure 3: Bland-Altman bias plot showing correlation between urine 
albumin analysed with the HemoCue® and that analysed using the 
laboratory method
Table III: Distribution of urine albumin measured semiquantitatively by the Clinitek® microalbumin POCT system compared with the quantitative laboratory 
method, using a albumin-to-creatinine ratio cut-off of 3.4 mg/mmol
Laboratory bACR < 3.4 mg/mmol
microalbuminuria negative
Laboratory ACR ≥ 3.4 mg/mmol
microalbuminuria positive Total
Laboratory ACR mean 
(range) in mg/mmol
















Total 130 74 204
a = Clinitek® albumin-to-creatinine ratios are semiquantitatively expressed as “normal”, “abnormal” or “high abnormal” correlating with the respective albumin-to-creatinine ratios 
of < 3.4, 3.4-33.9 and > 33.9 mg/mmol, b = albumin-to-creatinine ratio
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The linear regression analysis demonstrated a good 
correlation in the range of 5-150 mg/l for the HemoCue® 
system (y = 0.8557x + 0.2497y, r = 0.97), especially 
considering that presently there is no international 
calibrator for urine albumin. There was also a good 
correlation between the HemoCue® and laboratory 
albumin concentration (see Figure 2), with the laboratory 
albumin results being slightly higher than those of the 
HemoCue® (see Figure 3). The diagnostic accuracy of 
the two POCT systems as compared to our laboratory 
methods is illustrated in Table IV.
Table IV: The diagnostic accuracy of the two POCT systems for 





Sensitivity% (95% CI) 79.6 (70.6) 83.8 (73.0-91.0)
Specificity% (95% CI) 97.1 (92.2-99.1) 93.8 (87.8-97.1)
aPPV% (95% CI) 95.6 (88.4-98.6) 88.6 (78.2-94.6)
bNPV% (95% CI) 85.8 (79.1-90.7) 91.0 (84.6-95.1)
a = positive predictive value; b =  negative predictive value
The HemoCue® urine albumin POCT system is considered 
simple, very easy to use, and delivers rapid results (within 
two minutes). The cost per test compares favourably with 
the cost of a laboratory-based albumin determination. Both 
spot and timed urine specimens can be used with this 
system. This analyser measures urine albumin quantitatively, 
which allows for clinical decision-making and follow-up 
of patients. To date, it is the only POCT system for urine 
albumin on the market that delivers quantitative results. 
Haemoglobin, myoglobin, and most other drugs do not 
interfere with the interpretation of this test.4 Although the 
instrument delivers quantitative results, it does not correct 
the albumin concentration per creatinine, and false high or 
low values may be obtained for severely concentrated or 
diluted spot urine specimens. Another shortcoming of the 
HemoCue® POCT system is that its measurement range 
is only 5-150 mg/l. This means that for specimens with an 
albumin concentration above 150 mg/l, a dilution should 
be made with normal saline, which is time-consuming 
and may prove to be difficult for an inexperienced health 
professional in an office or clinic setting. The HemoCue® 
urine albumin analyser can only be used to analyse urine 
albumin concentrations, and is a rather costly instrument. 
Other factors that need to be taken into consideration are 
that the HemoCue® reagent needs to be refrigerated, and 
that visually turbid specimens should only be analysed after 
centrifugation, which may prove to be difficult in a clinic 
setting.
Clinitek® microalbumin dipsticks test for albumin and 
creatinine semiquantitatively by measuring colour changes 
on the strips using the Clinitek® status reflectance 
photometer, which calculates an ACR to allow for varying 
urine concentrations. The semiquantitative Clinitek® 
microalbumin urine dipstick albumin and creatinine results 
correlate well with the quantitative results of the laboratory 
method. This urine dipstick is easy to use, delivering rapid 
results. The Clinitek® status photometer is a multi-purpose 
analyser, and can also read Multistix® standard urine 
dipsticks, as well as βhCG cassettes. This is a cost-effective 
test, compared to the laboratory-determined ACR. Although 
the results expressed by this system are semiquantitative, 
the albumin is corrected for creatinine, eliminating the effect 
of variations in the urine concentration. The reagent strips 
for this test have a long shelf life, and need to be stored 
in a cool, dry place only. Refrigeration is not necessary. 
The dipsticks are easy to use and the instructions on the 
Clinitek® status analyser are clear and easy to follow, but 
the system is operator dependent. It is important to read 
the creatinine pad on the dipstick exactly 60 seconds after 
immersing the dipstick into the sample. The creatinine 
pad may continue to change colour after 60 seconds, and 
improper timing can cause the creatinine, and the resulting 
ACR, to be incorrect. There might be substances in the 
urine that interfere with the interpretation of the results. The 
presence of visible haemoglobin, or myoglobin, may cause 
falsely elevated results, for both the albumin and creatinine. 
According to the manufacturer, contamination of the urine 
with soaps, detergents, antiseptics, or preservatives other 
than boric acid may also affect the results.5 Substances that 
cause abnormal urine colour (such as drugs containing azo 
dyes, nitrofurantoin and riboflavin) may mask or enhance 
colour development on the pad, causing false positive or 
negative results. The results are only semiquantitative, and 
are not ideal for follow-up of patients.
In general, the drawback of POCT systems is that they are 
not sensitive or accurate enough to be used for diagnostic 
purposes. Sacks et al6 propose that screening tests for 
microalbuminuria should be positive in > 95% of patients 
with microalbuminuria, and that the positive tests should 
be confirmed by analysis in an accredited laboratory. Sacks 
et al6 also recommend that the analytical CV of methods 
used to measure microalbuminuria should be < 15%. In 
this study, the HemoCue® urine albumin POCT system 
fulfils these proposed specifications, but it is important to 
take into account that the HemoCue® POCT instrument 
measures the albumin concentration only, and does not 
correct for creatinine in a random spot urine specimen.
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The results of this study correlate with those of previously 
published studies that show a good correlation between the 
HemoCue® and a nephelometrically determined albumin 
concentration.7 Sarafidis et al8 found a sensitivity of 92%, a 
specificity of 98%, a positive predictive value (PPV) of 92%, 
and a negative predictive value (NPV) of 98%, compared 
with a immunoturbidimetric method in patients with various 
risk factors for chronic kidney disease and cardiovascular 
disease. In this study, the sensitivity of the HemoCue® 
was slightly lower (78.8%), but with similar specificity and 
predictive values.  
In this study, the performance of the Clinitek® microalbumin 
test was similar to, or better than, that reported in previously 
published studies. Le Floch et al9 found a sensitivity of 79%, 
a specificity of 81%, a PPV of 46%, and an NPV of 95%, 
in diabetic patients. Wilde et al10 found sensitivities for 
pregnant patients ranging from 19-59%, and specificities 
from 45.4-84.2%, with  sensitivity of 52.4% and a specificity 
of 97.6% in the community cohort. The differences in the 
various studies are probably as result of the diverse patient 
populations involved, as well as the inclusion or exclusion 
of macroalbuminuric specimens. The results in this study 
on diabetic patients confirm the findings reported by other 
investigators, namely that the Clinitek® microalbumin 
test is valuable, particularly in confirming the absence of 
microalbuminuria in urine specimens (the NPV in this study 
was 91.0%). 
A possible limitation of this study is that it was conducted in 
a laboratory environment, and all the analyses were carried 
out by one person. In a clinical setup, different people are 
likely to use the POCT systems, and a difference in the 
results might occur if the specimens are not all handled 
in the same way, or not used according to manufacturers’ 
recommendations. Our urine specimens were centrifuged 
before analysis, which will not be possible in the clinic 
setting, and this may influence results.
In conclusion, both the HemoCue® and the Clinitek® 
microalbumin POCT systems are easy to use, inexpensive, 
and reasonably accurate as screening methods. Although 
the HemoCue® test measures albumin concentration 
only, its sensitivity and specificity compared well with the 
Clinitek® POCT system, which determines the ACR.
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